Cooperation of PD-1 and LAG-3 in the exhaustion of CD4⁺ and CD8⁺ T cells during bovine leukemia virus infection

Tomohiro Okagawa, Satoru Konnai, Asami Nishimori, Naoya Maekawa, Shinya Goto, Ryoyo Ikebuchi, Junko Kohara, Yasuhiro Suzuki, Shinji Yamada, Yukinari Kato, Shiro Murata and Kazuhiko Ohashi

Abstract

Bovine leukemia virus (BLV) is a retrovirus that infects B cells in cattle and causes bovine leukemia after a long latent period. Progressive exhaustion of T cell functions is considered to facilitate disease progression of BLV infection. Programmed death-1 (PD-1) and lymphocyte activation gene-3 (LAG-3) are immunoinhibitory receptors that contribute to T-cell exhaustion caused by BLV infection in cattle. However, it is unclear whether the cooperation of PD-1 and LAG-3 accelerates disease progression of BLV infection. In this study, multi-color flow cytometric analyses of PD-1- and LAG-3-expressing T cells were performed in BLV-infected cattle at different stages of the disease. The frequencies of PD-1⁺LAG-3⁺ heavily exhausted T cells among CD4⁺ and CD8⁺ T cells was higher in the blood of cattle with B-cell lymphoma over that of BLV-uninfected and BLV-infected cattle without lymphoma. In addition, blockade assays of peripheral blood mononuclear cells were performed to examine whether inhibition of the interactions between PD-1 and LAG-3 and their ligands by blocking antibodies could restore T-cell function during BLV infection. Single or dual blockade of the PD-1 and LAG-3 pathways reactivated the production of Th1 cytokines, interferon-γ and tumor necrosis factor-α, from BLV-specific T cells of the infected cattle. Taken together, these results indicate that PD-1 and LAG-3 cooperatively mediate the functional exhaustion of CD4⁺ and CD8⁺ T cells and are associated with the development of B-cell lymphoma in BLV-infected cattle.

Introduction

Bovine leukemia virus (BLV) is a member of the genus Deltaretrovirus (subfamily Orthoretrovirinae, family Retroviridae) and is genetically related to human T-cell leukemia virus type 1 [1]. BLV infects B cells in cattle and is integrated into the host genome as a provirus [2, 3]. The majority (around 70%) of BLV infections in cattle remain clinically asymptomatic, referred to as aleukemic (AL). However, up to 30% of infected cattle develop persistent lymphocytosis (PL), characterized by non-malignant polyclonal expansion of IgM⁺CD5⁺ B cells, the majority of which harbor BLV provirus. After a long latent period, less than 5% of infected cattle develop malignant B-cell lymphoma in various lymph nodes, so-called enzootic bovine leukemia (EBL) [4]. During BLV infection in cattle, T-cell response is known to be suppressed in PL and EBL animals, but not in AL animals [5–12]. Suppression of T-cell proliferation in response to BLV antigens and Th1 cytokine production are observed in PL and EBL cattle and considered to be associated with disease progression [7–12].

To develop strategies to induce effective immune responses to BLV infection, previous studies have investigated the mechanism responsible for T-cell exhaustion [13–16]. A previous report has shown that the immunoinhibitory receptor programmed death-1 (PD-1) is upregulated in CD4⁺ and CD8⁺ T cells and is involved in the exhaustion of T-cell functions in BLV-infected cattle bearing B-cell lymphoma [13]. Further studies have confirmed the correlation between upregulation of lymphocyte activation gene-3 (LAG-3) on CD4⁺ and CD8⁺ lymphoma in various lymph nodes, so-called enzootic bovine leukemia (EBL) [4]. During BLV infection in cattle, T-cell response is known to be suppressed in PL and EBL animals, but not in AL animals [5–12]. Suppression of T-cell proliferation in response to BLV antigens and Th1 cytokine production are observed in PL and EBL cattle and considered to be associated with disease progression [7–12].
T cells and disease progression in BLV infection [14, 15]. Respective ligands of PD-1 and LAG-3, programmed death-ligand 1 (PD-L1) and major histocompatibility complex class II (MHC II), were upregulated in B cells including BLV-infected B cells in BLV-infected cattle [14–18]. We therefore hypothesized that PD-1 and LAG-3 cooperatively contribute to the development of T-cell exhaustion during disease progression of BLV infection. According to evidences from mouse models and human patients with chronic infections, PD-1+LAG-3+ T cells is heavily exhausted functionally and strongly associated with progression of several chronic infections [19].

However, our previous studies on BLV infection were analyzed expression of PD-1 and LAG-3 separately in independent experiments [13–15], thereby it was unknown whether PD-1 and LAG-3 express in the same T-cell populations and play immunosuppressive roles cooperatively during BLV infection. In addition, LAG-3 expression has been investigated in AL and PL cattle, but not in EBL animals yet [14, 15]. To unravel the immunosuppression mediated by LAG-3 during the development of bovine leukemia, expression level of the molecule should be investigated in EBL animals. Multi-color flow cytometric analysis detecting PD-1+LAG-3+ T cells requires sensitive monoclonal antibodies (mAbs) against bovine immunoinhibitory molecules. Thus, we have established anti-bovine PD-1 [13], anti-bovine PD-L1 [20], and anti-bovine LAG-3 mAbs [21]. In this paper, therefore, the dual expression of PD-1 and LAG-3 on T cells were first analyzed among BLV-infected cattle at different stages of the disease.

Moreover, blockade of the PD-1/PD-L1 and LAG-3/MHC II interactions using cross-reactive polyclonal antibodies increase Th1 cytokine responses and decrease BLV proviral load ex vivo in our previous reports [15, 16]. However, binding activity of the polyclonal antibodies was very weak and the blockade effect of the immunoinhibitory pathways seems to be underestimated in the previous study [16]. To address this problem, in this study, we tested the immunomodulatory activity of the novel sensitive mAbs against bovine PD-L1 and LAG-3 established in recent studies [20, 21] by ex vivo T-cell blockade assays using peripheral blood mononuclear cells (PBMCs) of BLV-infected cattle. This study will be helpful to estimate the therapeutic potential of PD-1 and LAG-3 blockade for BLV infection.

Materials and methods

Samples from cattle and BLV diagnosis

Blood samples collected from cattle (Holstein–Friesian and Japanese black) in dairy and beef farms in Japan between 2014 and 2016. Informed consent was obtained from all owners of the animals used in the study. BLV infection was diagnosed at Graduate School of Veterinary Medicine, Hokkaido University. Briefly, genomic DNA was extracted from whole blood using the Wizard Genomic DNA Purification kit (Promega, Madison, WI, USA). BLV was detected by nested PCR targeting the BLV long terminal repeat region (LTR) using the following primers: BLV-LTR1 5′-TGT ATG AAA GAT CAT GCC GAC-3′ and BLV-LTR533 5′-AAT TGT TTG CCG GTG TCT-3′ for the initial PCR, and BLV-LTR256 5′-GAG CTC TCT TGC TCC CGA GAC-3′ and BLV-LTR453 5′-GAA ACA AAC GCG GGT GCA AGC CAG-3′ for the second PCR [22]. The number of lymphocytes in the blood was counted using an automatic hematology analyzer Celltac α (Nihon Kohden, Tokyo, Japan). BLV-positive cattle were classified as AL or PL according to the lymphocyte counts as follows: AL, <10 000 cells/μL of blood; PL, ≥ 10 000 cells/μL of blood. Blood samples from cattle clinically diagnosed as bovine leukosis were confirmed as B-cell lymphoma by phenotypic analysis of tumor cells using flow cytometry as described previously [13, 23].

Cell preparation

PBMCs were purified from the blood samples using density gradient centrifugation on Percoll (GE Healthcare, Buckinghamshire, England, UK), washed three times with phosphate-buffered saline (PBS), and suspended in PBS.

Flow cytometric analysis of PD-1 and LAG-3 expression

Six-color analysis of PD-1- and LAG-3-expressing T cells was performed using fresh PBMCs obtained from the animals with various stages of the infection. PBMCs were incubated in PBS containing 10% goat serum (Sigma–Aldrich, St. Louis, MO, USA) at room temperature for 15 min to prevent nonspecific reactions. Cells were then washed and stained with anti-PD-1 monoclonal antibody (mAb) (5D2, rat IgG2a) [13] or rat IgG2a isotype control (R35-95, BD Biosciences, San Jose, CA, USA) for 20 min at room temperature, washed with PBS containing 1% bovine serum albumin (BSA; Sigma–Aldrich), and labeled with APC-conjugated anti-rat Ig antibody (Southern Biotech, Birmingham, AL, USA) for 20 min at room temperature. Cells were then washed and stained with anti-LAG-3 mAb (71-2D8, rat IgG1) [21] or rat IgG1 isotype control (R3-34, BD Biosciences) for 20 min at room temperature. Finally, cells were washed and incubated with anti-CD4-FITC mAb (CC8; Bio-Rad, Hercules, CA, USA) or anti-CD8-FITC mAb (CC63, Bio-Rad) in the presence of anti-TCRδ N24-APC/Cy7 mAb (anti-TCR δ chain; GB21A; Washington State University Monoclonal Antibody Center, Pullman, WA, USA), anti-CD3-PerCp/Cy5.5 mAb (MM1A; Washington State University, Pullman, WA, USA), and anti-CD8-FITC mAb (CC8, Bio-Rad, Hercules, CA, USA).
University Monoclonal Antibody Center), anti-IgM-PE/Cy7 mAb (IL-A30; Bio-Rad), and PE-conjugated anti-rat IgG1 mAb (G17E7; Southern Biotech) for 20 min at room temperature. mAbs GB21A, MM1A, and IL-A30 were conjugated with APC/Cy7, PerCp/Cy5.5, and PE/Cy7, respectively, using Lightning-Link Conjugation Kits (Innova Biosciences, Cambridge, England, UK). Cells were then washed and immediately analyzed by FACS Verse (BD Biosciences) and FCS Express 4 (De Novo Software, Glendale, CA, USA). The primary antibodies used in this experiment are shown in Table 1. More than 100,000 lymphocytes were analyzed among the samples.

**PBMC blockade assay and IFN-γ ELISA**

To determine whether the blockade of the PD-1/PD-L1 and LAG-3/MHC II interactions alter BLV-specific IFN-γ responses, PBMCs prepared from BLV-infected cattle were cultured with blocking mAbs anti-PD-L1 (4G12, rat IgG2a [20], anti-LAG-3 (71-2D8, rat IgG1) [21], or rat IgG (Sigma–Aldrich) in the presence of heat-inactivated supernatant (2%) of BLV-infected fetal lamb kidney cells (FLK-BLV) at 37 °C with 5% CO2 for 6 days. FLK-BLV supernatant contained BLV antigens to stimulate BLV-specific T cells in PBMC cultures as described previously [9]. The heat-inactivated supernatant (2%) of BLV-uninfected fetal lamb kidney cells (FLK) was used as a negative control antigen. All cell cultures were grown in 96-well round-bottomed plates (Corning Inc., Corning, NY, USA) containing 1 × 106 PBMCs in 250 μL RPMI 1640 medium (Sigma–Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (Cansera International, Etobicoke, ON, Canada), 200 IU/mL penicillin, 200 μg/mL streptomycin, and 0.01% v/v l-glutamine (Thermo Fisher Scientific, Waltham, MA, USA). Culture supernatants were then harvested and stored at −20 °C for IFN-γ ELISA. IFN-γ concentrations in the supernatants were determined using a bovine IFN-γ ELISA (Mabtech, Nacka Strand, Sweden) performed in duplicate according to the manufacturer’s protocol.

**PBMC blockade assay and flow cytometric analysis of IFN-γ/TNF-α-producing T cells**

To examine the effects of blocking mAbs on BLV-specific T-cell responses, in vitro blockade assay was performed. PBMCs were cultivated with 10 μg/mL of blocking mAbs anti-PD-L1 (4G12, rat IgG2a) [20], anti-LAG-3 (71-2D8, rat IgG1) [21], or rat IgG (Sigma–Aldrich) in the presence of 2% heat-inactivated FLK-BLV supernatant and 1 μg/mL of agonist mAbs anti-CD3 (MM1A; Washington State University Monoclonal Antibody Center) and anti-CD28 (CC220; Bio-Rad) at 37 °C with 5% CO2 for 18 h. 2% heat-inactivated FLK supernatant was used as a negative control antigen. All cell cultures were grown in 96-well round-bottomed plates (Corning Inc.) containing

### Table 1 Primary antibodies used in flow cytometric analysis of this paper

| Target | Isotype | Clone | Source (reference) | Fluorochrome | Conjugation or labeling |
|--------|---------|-------|-------------------|--------------|------------------------|
| **Flow cytometric analysis of PD-1 and LAG-3** | | | | |
| CD4 | Mouse IgG2a | CC8 | Bio-Rad | FITC | (Conjugated primary antibody) |
| CD8 | Mouse IgG2a | CC63 | Bio-Rad | FITC | (Conjugated primary antibody) |
| CD3 | Mouse IgG1 | MM1A | WSU monoclonal Antibody Center | PerCp/Cy5.5 | Lightning-Link PerCp/Cy5.5 Conjugation Kit (Innova Biosciences) |
| IgM | Mouse IgG1 | IL-A30 | Bio-Rad | PE/Cy7 | Lightning-Link PE/Cy7 Conjugation Kit (Innova Biosciences) |
| TCR1-N24 (δ chain) | Mouse IgG2a | GB21A | WSU monoclonal Antibody Center | APC/Cy7 | Lightning-Link APC/Cy7 Conjugation Kit (Innova Biosciences) |
| PD-1 | Rat IgG2a | SD2 | In house [13] | APC | APC-conjugated anti-rat Ig antibody (Southern Biotech) |
| LAG-3 | Rat IgG1 | 71-2D8 | In house [21] | PE | PE-conjugated anti-rat IgG1 antibody (Southern Biotech) |

| **Flow cytometric analysis of IFN-γ/TNF-α-producing T cells (intracellular staining)** | | | | |
| CD4 | Mouse IgG2a | CC8 | Bio-Rad | FITC | (Conjugated primary antibody) |
| CD8 | Mouse IgG2a | CC63 | Bio-Rad | PerCp/Cy5.5 | Lightning-Link PerCp/Cy5.5 Conjugation Kit (Innova Biosciences) |
| TCR1-N24 (δ chain) | Mouse IgG2a | GB21A | WSU monoclonal Antibody Center | Alexa Fluor 647 | Zenon Alexa Fluor 647 Mouse IgG2a Labeling Kit (Thermo Fisher Scientific) |
| IFN-γ | Mouse IgG1 | CC302 | Bio-Rad | PE | (Conjugated primary antibody) |
| TNF-α | Mouse IgG2a | CC328 | Bio-Rad | APC/eFluor780 | Streptavidin APC/eFluor780 (eBioscience) |

FITC: fluorescein isothiocyanate, PerCp: peridinin-chlorophyll-protein complex, Cy: cyanin, PE: phycoerythrin, APC: allophycocyanin.
$1 \times 10^6$ PBMCs in 250 μL RPMI 1640 medium (Sigma–Aldrich) as described above. BFA (10 μg/mL; Sigma–Aldrich) was added for the final 6 h to enhance intracellular cytokine staining signals by blocking transport processes. Cultured PBMCs were collected and incubated in PBS containing 10% goat serum as described above. Cells were then washed and stained with anti-CD4-FITC mAb (CC8; Bio-Rad), anti-CD8-PerCp/Cy5.5 mAb (CC63; Bio-Rad), and anti-TCR1-N24-Alexa Fluor 647 mAb (anti-TCR δ chain; GB21A; Washington State University Monoclonal Antibody Center) for 30 min at 4 °C. CC63 was conjugated with Zenon Alexa Fluor 647 Mouse IgG₂ Labeling Kit (Thermo Fisher Scientific). After surface staining, cells were fixed and permeabilized using FOXP3 Fix/Perm kit (BioLegend, San Diego, CA, USA) according to the manufacturer’s protocol. Cells were then stained with anti-IFN-γ-PE (CC302; Bio-Rad), anti-CD4-FITC mAb (CC8; Bio-Rad), anti-CD8-PerCp/Cy5.5 mAb (CC63; Bio-Rad), and anti-IFN-γ-PE (CC302; Bio-Rad) and anti-TCR1-N24-Alexa Fluor 647 mAb (anti-TCR δ chain; GB21A; Washington State University Monoclonal Antibody Center) for 30 min at 4 °C. Cells were then washed and incubated with streptavidin APC/eFluor780 (eBioscience, San Diego, CA) for 30 min at 4 °C. Finally, cells were washed and analyzed immediately using FACS Verse (BD Biosciences) and FCS Express 4 (De Novo Software). The primary antibodies used in this experiment are shown in Table 1. More than 10 000 lymphocytes were analyzed among the samples.

Statistics
Significant differences in the frequency of each T-cell subset in expression analyses among groups were identified using Kruskal–Wallis test. A Friedman test was used to compare the IFN-γ production and the frequency of each cytokine-producing T-cell subpopulation between groups in blockade assays. All statistical tests were performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). Differences were considered statistically significant when $P < 0.05$.

Results
Increased frequencies of heavily exhausted CD4+ and CD8+ T cells in BLV-infected cattle with B-cell lymphoma
Earlier studies have shown that immunoinhibitory receptors such as PD-1 and LAG-3 were upregulated and play an immunomodulatory role in T-cell exhaustion during BLV infection in cattle [13–15]. We therefore hypothesized that disease progression of BLV-infected cattle is associated with expansion of PD-1+LAG-3+ heavily exhausted T cells. To test this hypothesis, the cell-surface expression of PD-1 and LAG-3 on CD4+, CD8+, and γδ T cells was investigated by multi-color flow cytometry of PBMCs isolated from BLV-infected cattle in different disease stages (AL, PL, and EBL). As shown in Figures 1A, 2A, and 3A, CD4+γδTCR+, CD8+γδTCR+, or CD8−γδTCR+ T cells were gated in CD3+IgM− lymphocytes and then analyzed for expression of PD-1 and LAG-3. The percentage of PD-1+LAG-3+CD4+ T cells was significantly larger in the EBL animals than in the BLV-uninfected animals (Figure 1B). In the CD8+ T cell subset, the frequency of PD-1+LAG-3+CD8+ T cells was significantly higher in the EBL group than in the other BLV-infected and BLV-uninfected groups (Figure 2B).

Reactivation of IFN-γ production by PD-1 and LAG-3 blockade
Several studies have shown that Th1 response including IFN-γ production is impaired during disease progression of BLV infection, especially in PL cattle [7–12]. In this study, to determine whether BLV-specific IFN-γ response was restored by the blockade using novel anti-PD-L1 [20] and anti-LAG-3 mAbs [21], blockade assay were performed using PBMCs of BLV-infected AL and PL cattle. Single blockade using either anti-PD-L1 or anti-LAG-3 mAbs showed significantly increased production of IFN-γ from PBMCs of AL animals in response to BLV antigen (7.5- and 4.6-fold over control IgG, respectively) (Figure 4B). Notably, dual blockade by anti-PD-L1 and anti-LAG-3 mAbs
significantly enhanced IFN-γ response to BLV antigen in PBMCs of both AL and PL groups (16.4- and 6.7-fold over control IgG, respectively) (Figures 4A and B). There results show that BLV-specific IFN-γ response can be reactivated by the in vitro blockade of PD-1/PD-L1 and LAG-3/MHC II interactions in BLV-infected cattle, even with progressed disease.
Because we observed the enhancement of IFN-γ response to BLV antigen by the blockade of the immunoinhibitory pathways, it was important to determine which subsets of T cells were induced to produce Th1 cytokines in PBMC blockade. To address this issue, PBMC blockade assay was performed in the presence of BLV antigen and
agonist mAbs to CD3 and CD28, and then cells producing IFN-γ and TNF-α were analyzed in each T-cell subset by flow cytometry (AL n = 6, PL n = 2). As shown in Figure 5A, CD4+ CD8− γδ TCR+, or CD8− γδ TCR+ T cells were gated in lymphocytes and then analyzed for expression of IFN-γ and TNF-α. Consistent with the data of Figure 4, the frequency of IFN-γ producing cells in total lymphocytes significantly increased by the dual blockade using anti-PD-L1 and anti-LAG-3 mAbs (Figure 5B, left). Additionally, LAG-3 blockade significantly
enhanced TNF-α production in lymphocytes (Figure 5A, center). Remarkably, IFN-γ/TNF-α double producers are activated by anti-LAG-3 mAb alone and in combination with anti-PD-L1 mAb (Figure 5B, right). Phenotypic analyses of cytokine-producing T cells revealed that CD4+ and CD8+ T cells, but not CD8−γδ T cells, were induced to produce the larger amounts of Th1 cytokines by the blockade of the PD-1 and LAG-3 pathways (Figures 5C–E). Single or dual treatment of anti-PD-L1 and anti-LAG-3 mAbs induced significant increases in the percentages of IFN-γ+TNF-α+CD4+ T cells (Figure 5C, right). TNF-α production in CD4+ and CD8+ T cells was significantly enhanced by single blockade using anti-PD-L1 or anti-LAG-3 mAb (Figures 5C and D, center). Unexpectedly, the frequencies of IFN-γ-producing CD8−γδ T cells were significantly higher in cultures using anti-LAG-3 mAb with or without anti-PD-L1 mAb (Figure 5E, left). Overall, these results indicate that BLV-specific Th1 response can be reactivated by the blockade of the PD-1 and LAG-3 pathways in BLV-infected cattle.

**Discussion**

Cases of BLV infection and BLV-induced EBL in cattle have been increasing in Japan [24, 25]. Nevertheless, there is neither effective treatment nor vaccination to control BLV infection, which is due in part to the lack of understanding of the immunological mechanisms leading to immune evasion. During BLV infection, especially in the PL and EBL stages, T-cell exhaustion characterized by impaired proliferation of BLV-specific T cells and down-regulation of Th1 cytokines accelerates disease progression [7–12]. Previous studies have clarified the molecular mechanism responsible for this T-cell exhaustion, implicating immunoinhibitory receptors such as PD-1 and LAG-3 in this process [13–15]. PD-1 upregulation has been observed in CD4+ and CD8+ T cells in peripheral blood and lymph nodes of EBL cattle [13]. Expression level of LAG-3 upregulated on peripheral CD4+ and CD8+ T cells in PL cattle and correlated positively with lymphocytosis and negatively with IFN-γ expression in CD4+ T cells [15]. In the present study, we conducted immunophenotypic and functional analyses of PD-1- and LAG-3-expressing exhausted T cells in BLV-infected cattle with different stages of disease.

The immunophenotypic analyses have revealed that PD-1+LAG-3+ T cells are expanded in peripheral among CD4+ and CD8+ T cells during the EBL stage but not the PL stage. The tested EBL animals developed monoclonal or oligoclonal expansion of B cells in peripheral blood (data not shown); therefore, these observations indicate that PD-1+LAG-3+ T cells can be functionally exhausted and are associated with the tumor development. However, the contribution of these exhausted T-cell subsets to tumor phenotype and pathogenesis is not clear. In this study, no correlation was found between the frequency of exhausted T-cell subsets in EBL animals and age of the onset, disease parameters, or clinical signs (data not shown). Further immunophenotypic analysis of PD-1+LAG-3+ T cells in tumor lesions of EBL animals is desired to be conducted to address this issue.

In healthy cattle, PD-1 and LAG-3 are expressed mainly on CD4+ and CD8+ T cells, respectively [13, 21]. Indeed, PD-1+LAG-3+ and PD-1+LAG-3+ T cells were mainly observed in CD4+ and CD8+ T-cell subsets, respectively, of BLV-uninfected, AL and PL animals. In the EBL group, not only the median percentages of PD-1+LAG-3+ T cells but also that of PD-1+LAG-3+CD4+ and PD-1+LAG-3+CD8+ T cells were larger than the other groups. These results imply...
Figure 5  Effect of PD-1/PD-L1 and LAG-3/MHC II blockade on Th1 cytokine production in BLV-specific T cells. PBMCs (n = 8; AL n = 6, PL n = 2) were cultivated with 10 µg/mL each of blocking mAbs (anti-PD-L1 and anti-LAG-3 mAbs; 10 µg/mL) or rat IgG control in the presence of FLK-BLV antigen (2%) and anti-CD3 and anti-CD28 agonist mAbs (1 µg/mL each) for 18 h. A Gating strategy and representative dot plots for expression analyses of IFN-γ and TNF-α on total lymphocytes, CD4+ T cells, CD8+γδTCR− T cells, and CD8+γδTCR+ T cells from peripheral blood of an AL animal. Values in the quadrants indicate percentages of cells. Percentages of IFN-γ+ (left), TNF-α+ (center), IFN-γ+TNF-α+ cells (right) among total lymphocytes (B), CD4+ T cells (C), CD8+γδTCR− T cells (D), and CD8+γδTCR+ T cells (E) in PBMCs treated with blocking mAbs. Bars indicate group median response. Significant differences between each group were determined using Friedman test, where P < 0.05, P < 0.01, and P < 0.001, indicated by asterisks (*, **, and ***, respectively).
that upregulations of LAG-3 on CD4+ T cells and PD-1 on CD8+ T cells and subsequent co-expressions with other inhibitory receptors are remarkable change during the development of B-cell lymphoma in BLV-infected cattle.

A large number of γδ T cells are found in T-cell population of cattle, comprising up to 80% of T cells in peripheral blood of young calves, and 10–20% of T cells in adult cattle [26, 27]. Bovine γδ T cells have cytolytic and cytokine secretory properties similar to those of αβ T cells, thereby playing key roles in adaptive immunity of cattle [26, 27]. PD-1 expression is known to impair IFN-γ production and cytolytic function in human γδ T cells [28]. In addition, a previous study demonstrated increase of LAG-3+ γδ T cells in peripheral blood of cattle during acute anaplasmosis [29]. In contrast, this study found that the expression levels of PD-1 and LAG-3 were not changed on CD8+ γδ T cells during BLV infection. Further experimentation is required to confirm immunomodulatory role of PD-1 and LAG-3 on bovine T cells, but it seems that these immunoinhibitory receptors might play the major role in CD4+ and CD8+ αβ T-cell subsets, not in γδ T cells, in cattle bearing lymphoma.

The mechanism underlying the upregulation of PD-1 and LAG-3 is unclear in BLV infection, but evidences in humans and mice suggest that expression of PD-1 and LAG-3 is dependent on massive antigen presentation and the cytokine environment for a long period during chronic diseases [19, 30, 31]. Therefore, period post-infection could be associated with viral load and tumor development as well as the upregulation of PD-1 and LAG-3. The period post-infection of each tested animal is unknown because these animals are naturally infected with BLV. The experimental infection is helpful to investigate kinetics of the immunoinhibitory molecules throughout development of the disease. Co-upregulation of PD-1 and LAG-3 was observed in CD8+ T cells specific for viral or tumor antigens during chronic infection with lymphocytic choriomeningitis virus and human ovarian cancer [32, 33]. In BLV-infected cattle, PD-1 and LAG-3 are expected to be co-expressed on BLV-specific T cells. Confirmation of the relationship between PD-1+LAG-3+ T cells and antigen-specific immunosuppression in BLV infection requires MHC-peptide tetramers for the detection of BLV-specific T cells by flow cytometry.

A previous study has shown that proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins is impaired in PL animals and is almost lost in EBL animals, which is a critical evidence of the exhaustion of BLV-specific CD4+ T cells [8]. In this study, blockade of the immunoinhibitory receptor-ligand interactions using our novel blocking mAbs, anti-PD-L1 [20] and anti-LAG-3 mAbs [21], resulted in successful reactivation of IFN-γ production in response to whole BLV antigen even in PL animals. According to flow cytometric analysis of IFN-γ- and TNF-α-producing T cells, blockade of either PD-1/PD-L1 or LAG-3 was sufficient to activate double cytokine-producing multifunctional CD4+ T cells. These results suggest that the dual blockade has a potential to prevent disease progression by restoring anti-viral immunity during BLV infection. However, no significant correlation between the blockade effects and clinical parameters (proviral load, lymphocyte counts, and B cell occupancy in blood) was identified in the tested animals (data not shown). Additionally, most of the expression analyses and blockade assays were performed separately. The data of PD-1 and LAG-3 expression is available only for four animals which PBMCs samples were also tested for the blockade assay at the same time. Therefore, association between the frequency of PD-1+LAG-3+ T-cell subsets and the blockade outcomes is unclear. In this study, the blockade assays were also performed using PBMCs of EBL animals, but the number of T cells was so small that the level of IFN-γ production could not analyzed by IFN-γ ELISA and flow cytometry (data not shown). To evaluate the blockade effect in EBL animals, more sensitive methods to detect IFN-γ production from BLV-specific T cells are required, such as Enzyme-Linked ImmunoSpot assay with epitope peptides or immunogenic proteins, not whole viral protein [34, 35].

We have conducted immunophenotypic and functional analyses of exhausted T cells in various chronic infections in cattle, such as BLV infection, Johne’s disease, bovine anaplasmosis, and bovine mycoplasmosis [21, 29, 36, 37]. Findings in these studies reveal that T-cell exhaustion is caused by the upregulation of PD-1 and LAG-3 and presumably facilitates persistent infection and disease progression in cattle with chronic infections. BLV infection is one of the good models of infectious diseases causing T-cell exhaustion in cattle as well as the disease to be addressed.

Numbers of researchers and pharmaceutical companies have investigated antibody treatments that block these “immune checkpoint” in human, and anti-PD-1, anti-PD-L1, and anti-LAG-3 antibodies have been approved for various human cancers or evaluated on clinical trials with cancer patients [38, 39]. We recently established anti-bovine PD-1 and anti-bovine PD-L1 rat–bovine chimeric antibodies as candidate agents for blocking the PD-1/PD-L1 pathway in vivo [40, 41]. Administration of these chimeric antibodies to BLV-infected calves enhanced BLV-specific CD4+ T-cell proliferation and reduced BLV proviral load in vivo. Thus, targeting immunoinhibitory pathway is a significant strategy for the regulation of T-cell response to BLV.
infection in cattle. In order to establish novel immuno-therapies against BLV infection, additional studies are required to confirm the mechanisms underlying immuno-modulatory and anti-viral effects of blocking anti-body treatment in BLV-infected cattle.

Additional file

Additional file 1. Disease status and T-cell phenotype of individual EBL animals tested in this study. To evaluate the status of all the tested EBL cattle and its contribution to the phenotype of T cells, the individual data are shown as Additional file 1. The dataset includes age of onset, lymphocyte count in peripheral blood, BLV proviral load, tumor cell type, the percentage of B cells in peripheral blood, and the percentages of PD-1+LAG-3+ cells, PD-1+LAG-3− cells, and PD-1−LAG-3+ cells in CD4+, CD8+, and γδTCR+ T-cell subset of seven EBL animals tested in this study. Materials and methods related to only this dataset are also shown in additional file.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SK, SM, and KO were responsible for the conception and design of the study. TO, SK, AN, NM, SG, and, RP performed the experiments. TO, SK, JK, YS, YK, SM, and KO analyzed the data. JK, YS, SY, and YK provided intellectual input, laboratory materials, reagents and/or analytic tools. TO wrote the manuscript. SK, JK, YS, YK, SM, and KO contributed to the revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to Dr Hideyuki Takahashi, Dr Yasuyuki Mori, and Dr Tomio Ibayashi for their valuable advice and discussions. We would like to thank Enago for the English language review.

Ethics approval and consent to participate

Not applicable.

Funding

This work was supported by grants-in-aid for Scientific Research from Japan Society for the Promotion of Science (JSPS), by the Research Project for Improving Animal Disease Prevention Technologies to Combat Antimicrobial Resistance 2017–2021 FY, and by grants from the Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries, and Food Industry, Japan (number 260588; to SK) and the NARO, Bio-oriented Technology Research Advancement Institution (the special scheme project on regional developing strategy; grant 16817557 to SK). This research was partially supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research, BINDS) and a grant from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan for the Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University to YS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details

1 Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan. 2 Animal Research Center, Agriculture Research Department, Hokkaido Research Organization, Shintoku 081-0038, Japan. 3 Division of Bioresources, Research Center for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan. 4 Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo 001-0020, Japan. 5 Department of Antibody Drug Development, Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan. 6 Present Address: Laboratory of Immunology, Faculty of Pharmacy, Osaka Ohtani University, Tondabayashi 584-8540, Japan.

References

1. Sagata N, Yasunaga T, Tsuzuku-Kawamura J, Ohishi K, Ogawa Y, Iwasa Y (1985) Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses. Proc Natl Acad Sci U S A 82:677–681
2. Schwartz I, Bensaid A, Polack B, Perrin B, Berthelemy M, Levy D (1994) In vivo leukocyte tropism of bovine leukemia virus in sheep and cattle. J Virol 68:4589–4596
3. Mirsky ML, Olmstead CA, Da Y, Lewin HA (1996) The prevalence of proviral bovine leukemia virus in peripheral blood mononuclear cells at two subclinical stages of infection. J Virol 70:2178–2183
4. Gillet N, Florins A, Boxus M, Burteau C, Nigrò A, Vandermeers F, Balon H, Bouzar A-B, Defoche J, Burny A, Reichert M, Kettmann R, Willems L (2007) Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human. Retrovirology 4:18
5. Kabeya H, Ohashi K, Onuma M (2001) Host immune responses in the course of bovine leukemia virus infection. J Vet Med Sci 63:703–708
6. Frie MC, Goussens PM (2015) Bovine leukemia virus: a major silent threat to proper immune responses in cattle. Vet Immunol Immunopathol 163:103–114
7. Ohira K, Nakahara A, Konnai S, Okagawa T, Nishimori A, Maekawa N, Ikebuchi R, Kohara J, Murata S, Ohashi K (2016) Bovine leukemia virus reduces anti-viral cytokine activities and NK cytotoxicity by inducing TGF-β secretion from regulatory T cells. Immun Inflamm Dis 4:52–63
8. Orlik O, Splitter GA (1996) Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins. J Virol 70:7584–7593
9. Mager A, Masengo R, Mammerickx M, Letesson JJ (1994) T cell proliferative response to bovine leukemia virus (BLV): identification of T cell epitopes on the major core protein (p24) in BLV-infected cattle with normal haematological values. J Gen Virol 75:2223–2231
10. Amills M, Ramíja V, Norimine J, Olmstead CA, Lewin HA (2002) Reduced IL-2 and IL-4 mRNA expression in CD4+ T cells from bovine leukemia virus-infected cows with persistent lymphocytosis. Virology 304:1–9
11. Pyeon D, O’Reilly KI, Splitter GA (1996) Increased interleukin-10 mRNA expression in tumor-bearing or persistently lymphocytotic animals infected with bovine leukemia virus. J Virol 70:5706–5710
12. Pyeon D, Splitter GA (1998) Interleukin-12 p40 mRNA expression in bovine leukemia virus-infected animals: increase in alymphocytosis but decrease in persistent lymphocytosis. J Virol 72:6917–6921
13. Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, Suzuki Y, Murata S, Ohashi K (2013) Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro. Vet Res 44:59
14. Shirai T, Konnai S, Ikebuchi R, Okagawa T, Suzuki S, Sunden Y, Onuma M, Murata S, Ohashi K (2011) Molecular cloning of bovine lymphocyte activation gene-3 and its expression characteristics in bovine leukemia virus-infected cattle. Vet Immunol Immunopathol 144:462–467
15. Konnai S, Suzuki S, Shirai T, Ikebuchi R, Okagawa T, Sunden Y, Mingala CN, Onuma M, Murata S, Ohashi K (2013) Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus. Comp Immunol Microbiol Infect Dis 36:63–69
16. Ikebuchi R, Konnai S, Shirai T, Sunden Y, Murata S, Onuma M, Ohashi K (2011) Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro by PD-L1 blockade. Vet Res 42:103
17. Stone DM, Hof AJ, Davis WC (1995) Up-regulation of IL-2 receptor alpha and MHC class II expression on lymphocyte subpopulations from bovine
1. Kamphorst AO, Ahmed R (2013) Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol 25:381–388

2. Isaacson JA, Flaming KP, Roth JA (1998) Increased MHC class II and CD25 expression on lymphocytes in the absence of persistent lymphocytosis in cattle experimentally infected with bovine leukemia virus. Vet Immunol Immunopathol 64:235–248

3. Okagawa T, Konnai S, Deringer JR, Ueti MW, Scoles GA, Murata S, Ohashi K (2014) Bovine immune-inhibitory receptors contribute to the suppression of Mycobacterium avium subs. paratuberculosis-specific T-cell responses. Infect Immun 82:777–789

4. Tajima S, Takahashi M, Takahashi S, Yone SA, Watara S, Tanaka Y, Okuda M, Okada K, Aida Y (2003) A human mutant form of the tax protein of bovine leukemia virus (BLV) with enhanced transactivation activity increases expression and propagation of BLV in vitro but not in vivo. J Virol 77:1894–1903

5. Nishimori A, Konnai S, Okagawa T, Kaizaki R, Ikebuchi R, Nakahara A, Chiba Y, Ikeda M, Murata S, Ohashi K (2017) Identification of an atypical enzootic bovine leukemia in Japan by using a novel classification of bovine leukemia based on immunophenotypic analysis. Clin Vaccine Immunol 24:e00067–e00117

6. Murakami K, Kobayashi S, Konishi M, Kamayama K, Yamamoto T, Tsutsui T (2011) The recent prevalence of bovine leukemia virus (BLV) infection among Japanese cattle. Vet Microbiol 148:84–88

7. Murakami K, Kobayashi S, Konishi M, Kamayama K, Yamamoto T, Tsutsui T (2013) Nationwide survey of bovine leukemia virus infection among dairy and beef breeding cattle in Japan from 2009–2011. J Vet Med Sci 75:1123–1126

8. Guzman E, Price S, Poulsom H, Hope J (2012) Bovine γδ T cells: cells with multiple functions and important roles in immunity. Vet Immunol Immunopathol 148:161–167

9. Baldwin CL, Telfer JC (2015) The bovine model for elucidating the role of γδ T cells in controlling infectious diseases of importance to cattle and humans. Mol Immunol 66:34–47

10. Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, Tominumi N (2011) Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens. Eur J Immunol 41:345–355

11. Okagawa T, Konnai S, Deringer JR, Li, MW, Scates GA, Murata S, Ohashi K, Brown WC (2016) Cooperation of PD-1 and LAG-3 contributes to T-cell exhaustion in Anaplasma marginale-infected cattle. Infect Immun 84:2779–2790

12. Kamphorst AO, Ahmed R (2013) Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol 25:381–388

13. Sierro S, Romero P, Speiser DE (2011) The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 15:91–101

14. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DAA, Wherry EJ (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10:29–37

15. Maggioli MF, Palmer MV, Thacker TC, Vordermeier HM, Waters CR (2015) Characterization of effector and memory T cell subsets in the immune response to bovine tuberculosis in cattle. PLoS One 10:e0122571

16. Goto S, Konnai S, Okagawa T, Nishimori A, Maekawa N, Gondaira S, Higuchi H, Koike K, Tajima T, Kohara J, Ogasawara S, Kato Y, Suzuki Y, Murata S, Ohashi K (2017) Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis. Immun Inflamm Dis 5:355–363

17. Konnai S, Murata S, Ohashi K (2017) Immune exhaustion during chronic infections in cattle. J Vet Med Sci 79:1–5

18. Lipson EJ, Forde PM, Hammers SJ, Emens LA, Toebbe JM, Topalian SL (2015) Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 42:587–600

19. Sheridan C (2015) Immuno-oncology moves beyond PD-1. Nat Biotechnol 33:673–675

20. Okagawa T, Konnai S, Nishimori A, Ikebuchi R, Mlodziaro S, Nagata R, Kawaji S, Tanaka K, Kaizaki R, Murata S, Mori Y, Ohashi K (2016) Bovine immunoinhibitory receptors contribute to the suppression of Mycobacterium avium subs. paratuberculosis-specific T-cell responses. Infect Immun 84:2777–2790

21. Okagawa T, Konnai S, Ohashi K (2014) Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. Immunology 142:551–561

22. Kawasaki K, Kobayashi S, Konishi M, Kameyama K, Yamamoto T, Tsutsui T (2013) The recent prevalence of bovine leukemia virus (BLV) infection among Japanese cattle. Vet Microbiol 148:84–88

23. Nishimori A, Konnai S, Okagawa T, Maekawa N, Goto S, Ohashi K (2017) Identification of an atypical enzootic bovine leukemia in Japan by using a novel classification of bovine leukemia based on immunophenotypic analysis. Clin Vaccine Immunol 24:e00067–e00117

24. Murakami K, Kobayashi S, Konishi M, Kameyama K, Yamamoto T, Tsutsui T (2011) The recent prevalence of bovine leukemia virus (BLV) infection among Japanese cattle. Vet Microbiol 148:84–88

25. Murakami K, Kobayashi S, Konishi M, Kamayama K, Yamamoto T, Tsutsui T (2013) Nationwide survey of bovine leukemia virus infection among dairy and beef breeding cattle in Japan from 2009–2011. J Vet Med Sci 75:1123–1126

26. Guzman E, Price S, Poulsom H, Hope J (2012) Bovine γδ T cells: cells with multiple functions and important roles in immunity. Vet Immunol Immunopathol 148:161–167

27. Baldwin CL, Telfer JC (2015) The bovine model for elucidating the role of γδ T cells in controlling infectious diseases of importance to cattle and humans. Mol Immunol 66:34–47

28. Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, Tominumi N (2011) Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens. Eur J Immunol 41:345–355

29. Okagawa T, Konnai S, Deringer JR, Li, MW, Scates GA, Murata S, Ohashi K, Brown WC (2016) Cooperation of PD-1 and LAG-3 contributes to T-cell exhaustion in Anaplasma marginale-infected cattle. Infect Immun 84:2779–2790

30. Kamphorst AO, Ahmed R (2013) Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol 25:381–388